The Stem Cell Cannabinoid


“Many of us are cannabinoid deficient. A multitude of disorders and their symptoms come come from a deficiency… CBG, the stem molecule which quickly converts to CBD, THC and other cannabinoids.  CBG might turn out to be the most medicinal of the lot ."



CBG Molecule

CBG Molecule

Cannabigerol (CBG) is a cannabinoid found found in higher concentrations in Hemp as opposed to weed selectively bred for high psychoactive THC content. Most strains of medical and recreational cannabis have minor amounts CBG, somewhere between 0.1 and 1%.  The literature is very sparse and CBG is seldom quantified in industrial Hemp strains but average values appear to range from 0.2 to 2%.   It may be possible to interrupt the enzyme activity which converts CBG into THC especially.  Strains higher in CBG (est. 2-3%) have recently appeared in Europe and these new varieties are expected to appear on the market in the next year or so.  

Cannabigerol (CBG) is not psychoactive and is known to block the metabolic action, psychoactive effects of THC. CBG was shown to stimulate neurogenesis (brain cell growth). CBG also is antibacterial, anti-tumor, and helps with insomnia.  Based in the known and implied applications for CBG,

Cannabigerol (CBG)

CBG – The Next Big Cannabinoid after CBD


"CBG is the precursor, the stem cell, the mother of THC and CBD.  Until recently, the outstanding medicinal properties of this cannabis constituent were really studied."


All the major cannabinoids - THC, CBD and CBC in marijuana are biosynthesized from cannabigerol (CBG) by the rapid action of enzymes. Early harvesting therefore, doesn’t necessarily lead to especially high amounts of CBG. It may be possible to interrupt the enzymatic action to greatly elevate CBG concentrations.  With that said, it is feasible to extract separate CBG from Hemp in useful quantity.  This is surely that an elite cannabis based medicine supplier will take on some day in the near future.


"Like the other cannabinoids found in cannabis, CBG exhibits is exceptionally non-toxic as compared to most prescribed pharmaceutical preparations.  Observable negative side effects are practically absent in therapeutic doses."


CBG can modulate the fight or flight response. In technical lingo, CNG has a high affinity α2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist. It also binds to the CB2 receptor, but it's action is not well understood as yet (2016).  


Potential modulation of the α2-adrenergic receptor by CBG implies the following potential action;


  • Control fight and flight (stress, anxiety, anger, energy) Suppression of release of norepinephrine (noradrenaline)

  • Stimulates High blood pressure dropping to low.

  • Constriction of certain arteries, heart (coronary artery)

  • Constriction of some vascular smooth muscle, veins

  • Decrease motility of smooth muscle in gastrointestinal tract

  • Inhibition of lipolysis, the breakdown of complex fats (lipids) into fatty acids

  • Facilitates cognition, activity in the prefrontal cortex (PFC; working memory, attention, executive functioning, etc.)

  • Sedative efffects

  • Analgesia effects

Cannabigerol - the mama of all cannabinoids



synthesis of THC, CBG and more


CBG has been shown to :

  • Relieves pain.

  • Slow bacterial growth especially in certain species

  • Reduces seizures and convulsions.

  • Reduces inflammation systemically

  • Induce sleep.

  • Inhibits cancer cell growth

  • Promotes bone growth.

  • Stimulate growth of new brain cells


Conditions under Study:

  • Glaucoma:

  • Inflammatory Bowel Disease

  • Anti-Inflammatory Disorders

  • Epilepsy

  • Chronic Pain


Evidence that the Plant Cannabinoid cannabigerol blocks pain at the receptor - cellular level.


Evidence that cannabigerol can activate alpha(2)-adrenoceptors, bind to cannabinoid CB(1) and CB(2) receptors and block CB(1) and 5-HT(1A) receptors


Neuroprotective properties of cannabigerol in Huntington's Disease

Different plant-derived and synthetic cannabinoids have shown to be neuroprotective in experimental models of Huntington's disease We studied the effects of cannabigerol (CBG), CBG was extremely active as neuroprotectant. improving motor deficits and preserving striatal neurons. CBG reduced proinflammatory markers and improved the levels of antioxidant defenses.  In conclusion, our results open new research avenues for the use of CBG, alone or in combination with other phytocannabinoids or therapies, for the treatment of neurodegenerative diseases such as HD.


Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.


We investigated the effect of cannabigerol (CBG), a non-psychotropic Cannabis-derived cannabinoid, in a murine model of colitis. In conclusion (it worked), CBG attenuated murine colitis, reduced nitric oxide production in macrophages (effect being modulated by the CB2 receptor) and reduced ROS formation in intestinal epithelial cells. CBG could be considered for clinical experimentation in IBD patients.


Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist


This investigation has provided the first evidence that cannabigerol can activate α2-adrenoceptors, bind to cannabinoid CB1 and CB2 receptors and block CB1 and 5-HT1A receptors. It will now be important to investigate why cannabigerol produced signs of agonism more potently in the [35S]GTPγS binding assay than in the vas deferens and also whether it can inhibit noradrenaline uptake in this isolated tissue and in the brain.


Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats.


Here, we demonstrate for the first time that CBG elicits hyperphagia, by reducing latency to feed and increasing meal frequency, without producing negative neuromotor side effects. Investigation of the therapeutic potential of CBG for conditions such as cachexia and other disorders of eating and body weight regulation is thus warranted.


CBG – The Next Big Cannabinoid Strain


Mikey Kush 25-30% THC 3% Cannabigerol


Micky Kush is a 75% sativa cross between Sweet Irish Kush and Jack The Ripper. ... with earthy, kush flavor with lemon undertones, and deliver energetic, focused effects.... super high THC and CBG especially popular for treating nausea, pain, and depression.....medium height with a moderate to heavy yield, flowers in 7 and 8 weeks.


What is Cannabinoid Profiling?


Cannabinoid profiling informs patients about the concentration of active cannabinoids in their medicine....while THC is the most well-known cannabinoid, it is only responsible for a fraction of cannabis’ medicinal benefits. therefore it is wise to test for CBD, CBDA, CBN, CBG, CBC and THCA....


The Farmer Cannabis Cultivation Network


Bleu Berries (White Label) and Eldorado (Sativa Seedbank) show 1.8% and 1.5% CBG from tests. ..... some Sativa Landraces may have higher CBG but no test results I can find....




While it may take some time, have confidence that CBG-only strains will soon be as available as CBD varieties....


CBG – The Next Big Cannabinoid Strain


Mikey Kush strain is a Sativa-dominant strain testing with high levels of CBG and THC levels of 28.6%. CBG marijuana strains are becoming more available in Europe, and will most likely start to be seen on the shelves in North America soon.....

420EVALUATIONSONLINE:  If you find a strain that is high in CBG, you're going to need a medical doctor's recommendation to buy from a dispensary, cannabis clinic, marijuana grow cooperative or delivery service.  We specialize in same day 420 evaluations 100% online... We also provide Cannabis ID Cards and grower's permits valid in the state of California and Nevada.  These online processes follow the guidelines set by the Medical Board of California.


Interesting Posts